Oruka Therapeutics Announced A Private Investment In Public Equity Financing For Gross Proceeds Of Approximately $200M, Offering 5.6M Shares At $23/Share, 2,439 Shares Of Its Series A Non-voting Convertible Preferred Stock At $23,000 Per Share, And...
Oruka Therapeutics Announced A Private Investment In Public Equity Financing For Gross Proceeds Of Approximately $200M, Offering 5.6M Shares At $23/Share, 2,439 Shares Of Its Series A Non-voting Convertible Preferred Stock At $23,000 Per Share, And...
Oruka Therapeutics宣佈私募資金爲大約200 million美元，以每股23美元的價格提供5610000股普通股，以23,000美元的價格提供2439股A系列無表決權可轉換優先股，以...
Oruka Therapeutics Announced A Private Investment In Public Equity Financing For Gross Proceeds Of Approximately $200M, Offering 5.6M Shares At $23/Share, 2,439 Shares Of Its Series A Non-voting Convertible Preferred Stock At $23,000 Per Share, And Pre-funded Warrants To Purchase 680,000 Shares At $22.999 Per Pre-funded Warrant
Oruka Therapeutics宣佈對公募股權融資進行私人投資，總收益約爲2億美元，以每股23美元的價格發行560萬股股票，以每股23,000美元的價格發行2439股A系列無表決權可轉換優先股，以及以每份預籌認股權證22.999美元的價格購買68萬股股票的預籌認股權證
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。